Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interpectoral-pectoserratus plane block for minimally invasive aortic valve replacement
2023-509786-21-00Phase 4Authorised
- Sponsor
- AZ Maria Middelares
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in aortic valve disease (AVD) comparing Levobupivacaine interpectoral-pectoserratus plane block with Placebo/sham interpectoral-pectoserratus plane block (2 arms). Primary endpoint: Cumulative opioid consumption in the first 48 postoperative hours. Planned start Jun 2024; status: authorised.
02
Drugs
levobupivacaine
03
Conditions
aortic valve disease (AVD)
Beyond the preview
Go deeper on 2023-509786-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509786-21-00.